Equillium (LTS:0A4D) Total Stockholders Equity : $21.09 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Total Stockholders Equity?

Equillium's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $21.09 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Equillium's Book Value per Share for the quarter that ended in Mar. 2024 was $0.60. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Equillium's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.03.

Equillium Total Stockholders Equity Historical Data

The historical data trend for Equillium's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Total Stockholders Equity Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

41.85

69.85

66.51

31.94

22.57

Equillium Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															29.27	26.98	24.11	22.57	21.09

Equillium (LTS:0A4D) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Equillium's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(21.094	-	0)	/	35.2547
	=	0.60

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Equillium's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.424	+	0.295)	/	21.094
	=	0.03

Equillium Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Equillium's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (LTS:0A4D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (LTS:0A4D) Headlines

No Headlines